The Bioscan
AN INTERNATIONAL QUARTERLY JOURNAL OF LIFE SCIENCES
20(2): S.I (2), 48-53, 2026 www.thebioscan.com

PHARMACEUTICAL SUPPLY CHAIN RESILIENCE: LESSONS FROM RECENT GLOBAL CRISIS

H S Thrisha[1], Vishal Gupta[2], Aafiya Jahan M[3], Dr Amit. B. Patil[4*]

[1,3,4]Department of Pharmaceutics, JSS Academy of Higher Education and Research, Mysuru, Karnataka

[2]Department of Pharmacognosy, JSS Academy of Higher Education and Research, Mysuru, Karnataka

Corresponding Author: Dr Amit. B. Patil

DOI: https://doi.org/10.63001/tbs.2026.v21.i02.S.I(2).pp48-53

KEYWORDS
Supply chain management, Pharmaceutical Supply chain, economic impact, Resilience, Just in time

Received on:
10-02-2026
Accepted on:
08-03-2026
Published on:
05-04-2026

Abstract

Global crises such as the COVID-19 pandemic, have revealed critical vulnerabilities within pharmaceutical supply chains, underscoring the importance of building resilience to ensure continuous access to essential medicines. This review examines the key elements that contribute to the strength and adaptability of pharmaceutical supply networks, including supplier diversification, effective inventory management, adherence to regulatory standards, and the use of advanced technologies. Supply chain disruptions caused by natural disasters, geopolitical tensions, economic fluctuations, cyber threats, and operational challenges such as reliance on single-source suppliers and just-in-time inventory practices further highlight the need for robust strategies. Strengthening resilience involves thorough risk assessments, business continuity planning, and effective communication among stakeholders. Implementing predictive analytics, blockchain, and real-time monitoring systems can improve supply chain visibility, traceability, and proactive decision-making. Lessons learned from recent crises stress the value of cross-sector collaboration, strategic stockpiling, and ongoing process improvement. This review provides an in-depth analysis of pharmaceutical supply chain resilience, offering practical insights and strategies to mitigate risks and ensure reliable delivery of medicines during global emergencies.

1.INTRODUCTION

In the pharmaceutical industry, crisis management plays a pivotal role, particularly within supply chain management (SCM), as it safeguards the uninterrupted delivery of essential medicines to patients during emergencies and unforeseen events [1]. The pharmaceutical supply chain (PSC) represents a complex and interdependent network of manufacturers, suppliers, distributors, healthcare providers and regulators. Together, these entities oversee the transformation of raw materials into finished medicines and ensure their safe and timely distribution. Although this interconnected structure is indispensable, it also creates multiple points of vulnerability that can be exposed during crises [2].

Disruptive events including pandemics, geopolitical conflicts, natural disasters, transportation failures and large-scale product recalls have consistently highlighted weaknesses in pharmaceutical supply systems. Any interruption within this chain has direct consequences on patient safety and healthcare outcomes [3-4]. To manage these risks effectively, pharmaceutical companies must adopt robust crisis management strategies capable of maintaining operational continuity while preserving access to life-saving treatments. India, for example, has emerged as a global leader in supplying affordable, high-quality medicines. However, the country's pharmaceutical sector faces ongoing challenges such as fluctuating market demands, shorter product lifecycles, regulatory complexities and increasing global dependence on its production capacity. During public health emergencies, the ability to accurately forecast demand for medical commodities is essential. Misjudging needs or neglecting logistical gaps can intensify shortages and worsen crisis conditions [5-7].

During COVID-19 Pandemic:

The COVID-19 pandemic illustrated this vulnerability at an unprecedented scale. Border closures, lockdowns and factory shutdowns disrupted supply, demand and logistics simultaneously [8]. Reports suggest that more than 90% of Fortune

1000 companies experienced supply chain disruptions during the pandemic, forcing many multinational corporations (MNCs) to reassess their strategies and strengthen local or regional supplier networks. This context has brought the concept of supply chain resilience (SCR) to the forefront. Resilience can be described as a system's ability to withstand sudden shocks, adapt to evolving conditions and recover swiftly with minimal operational impact [9]. Within PSCs, resilience requires diversifying sources of raw materials and finished products, establishing alternative distribution routes, building reliable collaborations with stakeholders and using digital monitoring systems for real-time visibility. A resilient pharmaceutical supply chain not only minimizes economic losses and unmet medical needs but also fulfills a critical social responsibility by ensuring continuity of patient care. The last three decades, marked by recurring disease outbreaks and global emergencies, have underscored the importance of embedding resilience into healthcare systems [10-11].

The COVID-19 crisis, in particular, revealed overdependence on limited manufacturing hubs, insufficient stockpiling practices and poor supply-chain transparency [12]. These shortcomings disproportionately affected low- and middle-income countries, where restricted access to affordable medicines worsened existing inequalities. Thus, the ability to integrate resilience within pharmaceutical supply chains is essential for advancing global health security [13]. Beyond pandemics, natural disasters further demonstrate the necessity of proactive planning. While these events cannot be controlled, their impact can be mitigated through preparedness measures such as safety stock maintenance, flexible logistics arrangements and continuity planning. Ultimately, competition in the modern pharmaceutical sector extends beyond individual companies, it is determined by the strength and adaptability of their supply chains. Therefore, building resilience into pharmaceutical SCM is not merely an operational advantage but a fundamental requirement for ensuring healthcare stability and patient safety in times of crisis [14-15].

KEY DISRUPTIONS IMPACTING PHARMACEUTICAL SUPPLY CHAINS:

Natural Disasters and Environmental Factors:

Unpredictable environmental events and natural disasters represent a major threat to the stability of pharmaceutical supply chains. Phenomena such as earthquakes, floods and hurricanes can damage production facilities, interrupt critical transport networks and reduce workforce availability. Likewise, global health emergencies including the COVID-19 pandemic demonstrated how fragile international supply chains can be, with widespread shortages of essential medicines, personal protective equipment (PPE) and other critical products. The repercussions of such disruptions are felt throughout the supply chain, from sourcing raw materials to delivering finished products to hospitals and patients [16-17].

Examples: Earthquakes, floods, hurricanes and public health emergencies such as pandemics (e.g., COVID-19).

Implications for Manufacturing, Distribution and Continuity of Supply:

The effects of environmental crises on pharmaceutical operations are often far-reaching. Manufacturing plants may face shutdowns due to structural damage or lack of raw material inputs, resulting in delays and diminished production capacity. Distribution systems are also vulnerable, as damage to roads, ports and storage facilities can delay or prevent the movement of goods. These interruptions can compromise supply continuity, creating shortages of vital medicines and healthcare products at a time when demand is at its peak. Ultimately, such shortages pose a direct threat to patient care and can strain public health systems severely [18].

ECONOMIC AND POLITICAL DISRUPTIONS:

Economic policies and political dynamics exert a strong influence on the continuity of pharmaceutical supply chains. Measures such as tariffs, export controls and trade restrictions can significantly increase the cost of sourcing raw materials and distributing finished medicines. These additional expenses often squeeze manufacturers' profit margins and eventually translate into higher costs for consumers and healthcare systems. Geopolitical conflicts or diplomatic tensions further complicate supply continuity by disrupting trade corridors and delaying the movement of essential materials. Such uncertainties create instability across the supply chain, making it difficult for companies to design reliable strategies or ensure consistent delivery of pharmaceutical products [19].

Examples: Trade restrictions, tariffs, recessions and geopolitical conflicts.

Consequences of Economic Downturns and Political Instability:

Economic recessions and political unrest can further intensify vulnerabilities within supply networks. Reduced consumer spending and declining investment during economic slowdowns often lead to a drop in demand for pharmaceuticals, compelling companies to scale back production and limit inventory. Meanwhile, political turbulence such as frequent policy shifts, sudden regulatory reforms, or civil disturbances undermines operational stability by complicating compliance requirements and obstructing smooth manufacturing or distribution processes. Together, these factors foster a volatile environment for pharmaceutical supply chains, heightening the risk of medicine shortages and undermining the timely availability of essential treatments [20].

SUPPLY CHAIN VULNERABILITIES:

Reliance on Single Suppliers:

One of the most significant weaknesses in pharmaceutical supply networks is the dependence on a single provider for critical raw materials or components. This form of reliance increases the likelihood of disruption if that supplier encounters production failures, regulatory barriers, or logistical challenges [21]. For example, if the only manufacturer of a key active pharmaceutical ingredient (API) faces operational difficulties, the resulting shortage can affect the entire drug production cycle, ultimately limiting availability to patients. To reduce this risk, companies are advised to diversify sourcing channels and establish backup strategies that ensure continuity even during unexpected interruptions [22].

Limitations of Just-in-Time Inventory Systems:

The just-in-time (JIT) model, though widely used to lower storage expenses and enhance efficiency, can expose the pharmaceutical sector to substantial risks [23]. This system operates by scheduling the arrival of materials precisely when required for production, thereby minimizing inventory levels. However, such an approach leaves no margin for delays or errors. Even minor disturbances such as transportation slowdowns, supply shortages, or sudden demand increases can halt production and cause critical medicine shortages. While JIT improves operational efficiency, it demands a supply chain that is exceptionally resilient and consistently reliable, which is often difficult to maintain in volatile global markets [24].

TECHNOLOGICAL DISRUPTIONS:

Cybersecurity Threats and Digital Vulnerabilities:

With the rapid adoption of digital technologies and interconnected platforms, pharmaceutical supply chains are increasingly exposed to cyber risks. Cyber intrusions can compromise sensitive business and patient data, disrupt daily operations and impose significant financial losses [25]. For instance, a cyberattack targeting a manufacturer or distributor could lead to theft of proprietary information, alteration of

digital records, or suspension of production processes. To counter these threats, organizations must adopt robust cybersecurity frameworks, enforce strict data protection protocols and implement real-time monitoring systems to ensure operational continuity.

Failures in Technology and Their Consequences:

Apart from intentional cyber threats, unanticipated technological malfunctions such as hardware breakdowns, software bugs, or large-scale system outages pose substantial risks to pharmaceutical operations. These failures can trigger production delays, weaken inventory accuracy and disrupt coordination among supply chain partners [26]. A breakdown in automated manufacturing lines could halt drug production, whereas errors in inventory management systems may cause either shortages or excessive stock levels. Proactive maintenance, backup systems and contingency planning are therefore essential to reducing the adverse effects of technology-driven disruptions on supply chain performance.

APPROACHES TO HANDLING SUPPLY CHAIN DISRUPTIONS:

Risk Assessment and Management:

Resilient supply chains are built on the foundation of proactive risk identification. For pharmaceutical networks, this involves assessing both internal weaknesses and external threats such as supplier dependency, political instability, natural hazards and technological breakdowns. Mapping these vulnerabilities enables organizations to design focused mitigation strategies that reduce exposure to disruption [27].

Tools for Risk Evaluation:

Multiple analytical frameworks are available to support risk assessments. SWOT analysis (Strengths, Weaknesses, Opportunities, Threats) helps companies evaluate internal and external conditions influencing supply chain stability. Meanwhile, Failure Modes and Effects Analysis (FMEA) systematically identifies weak points in processes, predicts their likely outcomes and assists in ranking risks by severity. These structured tools allow firms to act preemptively rather than reactively [28].

Supplier and Manufacturing Diversification:

Dependence on a single supplier or production facility creates significant vulnerabilities. To reduce this exposure, companies are increasingly adopting multi-sourcing strategies and spreading production across geographically diverse sites. By decentralizing supply and manufacturing, organizations can ensure that if one supplier or region is compromised, alternative sources can sustain the flow of critical medicines [29].

Evidence from Industry Practice:

During the COVID-19 pandemic, organizations with diversified procurement and manufacturing strategies maintained greater continuity than those concentrated in limited locations. Such examples highlight the importance of supplier and facility diversification as a resilience-building strategy [30].

Inventory Management and Strategic Stockpiling:

Inventory planning requires striking a balance between efficiency and security. The Just-in-Time (JIT) approach minimizes inventory costs but provides little buffer against disruption. In contrast, the Just-in-Case (JIC) model builds reserves that protect against uncertainty but raise holding costs. An effective resilience strategy integrates both models, maintaining lean operations while ensuring enough stock to absorb shocks [31].

Safety Stock for Essential Medicines:

For life-saving drugs and essential medical products, maintaining strategic safety stocks is crucial. These reserves should be based on risk assessments, forecasted demand and expected lead times. Such planning reduces the likelihood of shortages during emergencies and safeguards continuity of patient care [32].

Harnessing Technology and Analytics:

Technological innovation provides powerful tools for anticipating and managing risks. Artificial intelligence (AI) and advanced analytics allow for predictive modeling, helping organizations detect potential disruptions before they occur. Real-time data monitoring further enhances agility, enabling supply chains to adapt quickly to changing circumstances [33].

Blockchain for Transparency:

Blockchain technology improves traceability by creating secure, immutable records across the supply network. This not only strengthens product authentication and reduces counterfeit risks but also enables rapid problem identification during crises. Enhanced transparency ultimately fosters trust and strengthens supply chain resilience [34].

Collaboration and Communication:

Strong collaboration across the supply chain between manufacturers, suppliers, regulators and distributors is critical for managing disruption. Partnerships foster resource sharing, aligned objectives and coordinated responses to crises [35]. Equally important is clear and timely communication. Structured communication plans ensure that stakeholders remain informed about supply chain status, risks and mitigation measures. This transparency reduces uncertainty, aligns expectations and ensures coordinated crisis response [36].

Regulatory Compliance and Adaptive Flexibility:

Regulatory challenges often intensify during crises. To remain compliant while sustaining operations, organizations must closely monitor evolving guidelines and work with regulators to secure approvals or temporary waivers where necessary.

Flexibility is also vital. Companies may need to adapt workflows, incorporate new technologies, or redesign supply networks to meet regulatory demands without compromising safety or quality. This balance of compliance and adaptability ensures continuity of supply and preserves patient trust in medicines [37].

Managing Crises within Pharmaceutical Supply Networks:

The pharmaceutical sector requires robust crisis management frameworks to minimize risks and maintain supply chain continuity. Recent research in process operations and management emphasizes supply chain optimization, focusing on facility design, production scheduling, inventory management and capacity planning. Designing supply chains in this industry is uniquely challenging, as firms must balance projected demand with uncertain outcomes of clinical trials, competitor strategies and tightening regulations, all while operating under narrowing profit margins. Effective capacity utilization, infrastructure investment and careful pipeline planning are therefore critical. At the operational level, flexibility is often limited, making coordinated inventory management, supply chain debottlenecking and decoupling strategies vital for responsiveness. Many supply chain inefficiencies stem from internal processes rather than external demand, highlighting the importance of rethinking organizational practices and supplier customer relationships. Collaboration also plays a decisive role in crisis response [38].

Latonen et al. (2023) [39] introduced a framework illustrating how pharmaceutical crisis management is structured through cross-sector partnerships, government-led committees and stakeholder collaboration. Information sharing, resource pooling and joint problem-solving enable resilience and continuity during disruptions. Earlier, Shah (2004) [40] emphasized that pharmaceutical supply chains initially centered on supply security to ensure efficient product delivery. Today, however, supply chains are evolving beyond material flows to include the

broader value chain, encompassing innovation, process development and production planning. This shift opens new research opportunities, with process and systems engineering approaches well positioned to address the complexities of modern pharmaceutical networks.

Establishing a Structured Crisis Management Approach:

Effective crisis management in the pharmaceutical supply chain requires assembling a multidisciplinary team that includes experts in operations, logistics, regulatory affairs and legal matters. Developing a structured crisis management plan ensures that responsibilities are clearly defined and actions during emergencies are well coordinated. Such a plan should cover resource allocation, communication strategies and contingency measures for different scenarios. Breaking down the planning process into smaller, manageable components allows risks to be identified systematically without being overwhelmed by the complexity of potential crises.

A practical framework for crisis management typically involves five key steps [41]:

1. **Establish the crisis management team:** Form a leadership group that includes representatives from public relations, legal, security and other critical functions to oversee crisis planning and execution.
2. **Risk evaluation:** Conduct brainstorming sessions and use tools such as a risk register to identify, categorize and estimate the likelihood of different threats.
3. **Business impact assessment:** Work with the leadership team to analyze how high-probability risks could affect operations, finances, reputation, customer retention, or regulatory compliance.
4. **Response preparation:** Define specific actions for each risk scenario, such as engaging with customers, securing IT systems, or assessing damages in the case of a cyberattack.
5. **Plan reinforcement:** Incorporate activation protocols, emergency contact lists and collaborative mechanisms with stakeholders. The plan should also detail communication approaches both written and verbal for effective coordination during disruptions.

Strategies for Strengthening Supply Chain Resilience [42-43]:

Enhancing supply chain flexibility requires identifying alternative suppliers and maintaining safety stock to reduce the risk of disruption. Strong vendor relationships and open communication channels further ensure reliability and resilience. Despite preventive measures, crises may still arise from events such as product recalls, trial failures, or cyber threats, making a proactive crisis communication strategy essential.

Key components of a pharmaceutical crisis management strategy include:

1. **Risk Assessment:** Systematically identify vulnerabilities such as natural disasters, geopolitical instability, supplier failures, or pandemics and establish a crisis team to mitigate them.
2. **Business Continuity Planning (BCP):** Prepare contingency measures, backup suppliers and clear communication channels to maintain operations during emergencies.
3. **Supplier Relationship Management:** Diversify sourcing, regularly evaluate supplier reliability and maintain strong domestic and international partnerships.
4. **Inventory Management:** Balance stock levels using forecasting tools and real-time monitoring to prevent shortages while ensuring continuity during disruptions.
5. **Collaboration & Communication:** Partner with regulators, suppliers and industry peers to share resources, expertise and timely updates during crises.
6. **Technology Integration:** Apply analytics, tracking systems and supply chain software to improve visibility, predict risks and respond proactively.
7. **Contingency Planning:** Establish backup production and distribution systems to minimize downtime from unexpected demand surges or facility closures.
8. **Regulatory Compliance:** Ensure adherence to GMP standards, quality control and evolving regulatory requirements.
9. **Training & Preparedness:** Conduct regular training, drills and simulations so employees are well-versed in crisis protocols.
10. **Continuous Improvement:** Review crisis responses post-event, integrate lessons learned and adapt strategies to evolving industry risks.

FUTURE TRENDS AND EMERGING STRATEGIES:

The evolution of pharmaceutical supply chains is increasingly driven by digital transformation, often referred to as Supply Chain 4.0. Integration of technologies such as the Internet of Things (IoT), artificial intelligence (AI), and machine learning enables real-time monitoring of product location, condition, and movement, enhancing visibility and operational control. AI and machine learning further optimize processes, detect inefficiencies, and predict potential disruptions, allowing supply chains to respond rapidly and adapt to changing conditions. Predictive Analytics is becoming a vital tool for proactive disruption management. By analyzing historical data and identifying patterns, predictive models can anticipate delays, equipment failures, or demand surges, enabling pre-emptive actions such as adjusting inventory, rerouting shipments, or activating contingency plans. This predictive capability strengthens supply chain resilience and ensures continuity amid unforeseen challenges. Sustainability and Ethical Sourcing are increasingly recognized as core components of resilient supply chains. Sustainable practices including reducing waste, minimizing carbon footprints, optimizing resource use, and adopting eco-friendly packaging enhance long-term stability and regulatory compliance. Ethical sourcing, which emphasizes fair labor practices, responsible resource use, and humane working conditions, safeguards company reputation and mitigates risks of disruptions due to labor disputes, environmental violations, or reputational damage. Investing in sustainable and ethical supply chain practices builds stronger supplier relationships and supports a resilient, environmentally responsible pharmaceutical supply network.

2. CONSLUSION

The recent global crises, including the COVID-19 pandemic, have underscored the critical importance of resilience in pharmaceutical supply chains. Disruptions caused by natural disasters, geopolitical tensions, economic fluctuations, and technological challenges highlighted vulnerabilities across production, distribution, and procurement processes. Developing robust crisis management strategies, diversifying suppliers, maintaining strategic safety stocks, leveraging technology, and fostering strong stakeholder collaboration are essential measures to mitigate risks. A resilient pharmaceutical supply chain not only ensures the continuous availability of essential medicines but also enhances regulatory compliance, operational efficiency, and public health outcomes. By integrating these insights into supply chain management practices, pharmaceutical companies can strengthen their capacity to respond effectively, safeguard patient care, and maintain global healthcare stability.

3. REFERENCES

- Mills J, Schmitz J, Frizelle G. A strategic review of "supply networks". Int J Op Product Manag. 2004;24(10):1012–36. doi: 10.1108/01443570410558058.
- Christopher M. Logistics and supply chain management. London: Pearson Education; 2022.
- Mehralian G, Rajabzadeh Gatari A, Morakabati M, Vatanpour H. Developing a suitable model for supplier selection based on supply chain risks: an empirical study from Iranian pharmaceutical companies. Iran J Pharm Res. 2012;11(1):209–19.
- Rajabzadeh Ghatari A, Mehralian G, Zarenezhad F, Rasekh HR. Developing a model for agile supply: an empirical study from Iranian pharmaceutical supply chain. Iran J Pharm Res. 2013;12(Suppl):193–205.
- Heckmann I, Comes T, Nickel S. A critical review on supply chain risk – Definition, measure and modeling. Omega. 2015;52:119–32. doi: 10.1016/j.omega.2014.10.004.
- Fiksel J. Sustainability and resilience: toward a systems approach. Sustain: Sci Pract Polic. 2017;2(2):14–21. doi: 10.1080/15487733.2006.11907980.
- Brandon-Jones E, Squire B, Autry C, Petersen KJ. A Contingent Resource-Based Perspective of Supply Chain Resilience and Robustness. J Suppl Chain Manag. 2014;50(3):55–73. doi: 10.1111/jscm.12050.
- Mukherjee S. Emerging Infectious Diseases: Epidemiological Perspective. Indian J Dermatol. 2017;62(5):459–67. doi: 10.4103/ijd.IJD_379_17.
- Sherman E. Coronavirus impact: 94% of the Fortune 1000 are seeing supply chain disruptions. New York: Fortune; 2020. Available from: https://fortune.com/2020/02/21/fortune-1000-coronavirus-china-supply-chain-impact/
- Kumar B, Sharma A. Managing the supply chain during disruptions: Developing a framework for decision-making. Indust Market Manag. 2021;97:159–72. doi: 10.1016/j.indmarman.2021.07.007.
- Mishra R, Singh RK, Subramanian N. Impact of disruptions in agri-food supply chain due to COVID-19 pandemic: contextualised resilience framework to achieve operational excellence. Int J Log Manag. 2021;33(3):926–54. doi: 10.1108/ijlm-01-2021-0043.
- Choi T, Narayanan S, Novak D, Olhager J, Sheu JB, Wiengarten F. Managing extended supply chains. J Bus Log. 2021;42(2):200–6. doi: 10.1111/jbl.12276.
- Donthu N, Gustafsson A. Effects of COVID-19 on business and research. J Bus Res. 2020;117:284–9. doi: 10.1016/j.jbusres.2020.06.008.
- Verma S, Gustafsson A. Investigating the emerging COVID-19 research trends in the field of business and management: A bibliometric analysis approach. J Bus Res. 2020;118:253–61. doi: 10.1016/j.jbusres.2020.06.057.
- CW, Ketchen DJ, Darby JL. Pandemics and Supply Chain Management Research: Toward a Theoretical Toolbox(). Decis Sci. 2020;51(4):838–66. doi: 10.1111/deci.12468
- Ivanov D. Predicting the impacts of epidemic outbreaks on global supply chains: A simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case. Transp Res Part E Logist Transp Rev. 2020;136:101922.
- Craighead CW, Blackhurst J, Rungtusanatham MJ, Handfield RB. The severity of supply chain disruptions: design characteristics and mitigation capabilities. Decis Sci. 2007;38(1):131-56.
- Blackhurst J, Dunn KS, Craighead CW. An empirically derived framework of global supply resiliency. J Bus Logist. 2011;32(4):374-91.
- Tang O, Musa SN. Identifying risk issues and research advancements in supply chain risk management. Int J Prod Econ. 2011;133(1):25-34.
- Wagner SM, Bode C. An empirical investigation into supply chain vulnerability. J Purch Supply Manag. 2006;12(6):301-12.
- Kilpatrick J, Barter L. COVID-19: Managing supply chain risk and disruption. Deloitte Insights. 2020. Available from: https://www2.deloitte.com/global/en/pages/risk/articles/covid-19-managing-supply-chain-risk-and-disruption.html.
- Ivanov D. Supply Chain Viability and the COVID-19 pandemic: A conceptual and formal generalisation of four major adaptation strategies. Int J Prod Res. 2020;58(10):2904-15.
- Lee HL. The triple-A supply chain. Harv Bus Rev. 2004;82(10):102-12. 16. Manuj I, Mentzer JT. Global supply chain risk management strategies. Int J Phys Distrib Logist Manag. 2008;38(3):192-223.
- Sharma A, Adhikary A, Borah SB. Covid-19's impact on supply chain decisions: Strategic insights from NASDAQ 100 firms using Twitter data. J Bus Res. 2020;117:443-9.
- Sodhi MS, Son B-G, Tang CS. Researchers' perspectives on supply chain risk management. Prod Oper Manag. 2012;21(1):1-13.
- Simchi-Levi D, Schmidt W, Wei Y. From superstorms to factory fires: Managing unpredictable supply-chain disruptions. Harv Bus Rev. 2014;92(1/2):96-101.
- Kim YH, Tang CS. Socially responsible and sustainable supply chains: a framework for analysis. Oper Res Perspect. 2015;2:54-64.
- Handfield RB, Graham G, Burns L. Corona virus, tariffs, trade wars and supply chain evolutionary design. Int J Oper Prod Manag. 2020;40(10):1649-60.
- Araz OM, Choi TM, Olson DL, Salman FS. Data analytics for operational risk management. Decis Sci. 2020;51(6):1316-42.
- Sarkis J. Supply chain sustainability: learning from the COVID-19 pandemic. Int J Oper Prod Manag. 2020;41(1):63-73.
- Manda, P., Popescu, C., Juluri, A. et al. Micronized Zaleplon Delivery via Orodispersible Film and Orodispersible Tablets. AAPS PharmSciTech 19, 1358–1366 (2018).
- Lakshmi Narasimha Rao, K., Praneeth Rao, K. Development and Validation of a Stability-Indicating LC Method for Determination of Bexarotene in Softgel Dosage Formulation. Chromatographia 80, 1211–1224 (2017).
- Kakulamarri PR, Alikatte KL, Mateti UV (2016) Transdermal Iontophoresis of Non-Polar Drugs: A Mini Review. J Pharm Drug Deliv Res 5:3
- Kakullamarri PR, Rao KLN (2017) Enhanced Bioavailability and Anticancer Activity of Vitamin Analogs. J Bioequiv Availab 9: 439-441.
- Bode C, Macdonald JR. Stages of supply chain disruption response: direct, constraining, and restoring response capabilities. Int J Phys Distrib Logist Manag. 2017;47(2/3):281-99.
- Paul SK, Chowdhury P. A production recovery plan in manufacturing supply chains for a high-demand item during COVID-19. Int J Phys Distrib Logist Manag. 2020;51(2):104-25.
- Schotter AP, Mudambi R, Doz YL, Gaur A. Boundary spanning in global organizations. J Manage Stud. 2017;54(4):403-21
- Durugbo, C. M., & Al-Balushi, Z. (2022). Supply chain management in times of crisis: a systematic review. Management Review Quarterly, 73. https://doi.org/10.1007/s11301-022-00272-x
- Latonen, S. H., Suominen, R. M., Juppo, A. M., Airaksinen, M., & Seeck, H. (2023). Organisation of cross-sector collaboration and its influence on crisis management

effectiveness among pharmaceutical supply chain stakeholders during the COVID-19 pandemic. Public Health, 222, 196–204. https://doi.org/10.1016/j.puhe.2023.06.042
- Shah, N. (2004). Pharmaceutical supply chains: key issues and strategies for optimisation. Computers & Chemical Engineering, 28(6-7), 929–941. https://doi.org/10.1016/j.compchemeng.2003.09.022
- Asana. (2021, August 16). What Is a Crisis Management Plan? (6 Steps to Create One) • Asana. Retrieved from Asana website: https://asana.com/resources/crisis-management-plan
- Tunisini, A., Harrison, D., & Bocconcelli, R. (2023). Handling resource deficiencies through resource interaction in business networks. Industrial Marketing Management, 109, 154–163. https://doi.org/10.1016/j.indmarman.2022.12.016
- Corbae, M. (2023, August 9). Crisis Communication Plans in Pharma. Retrieved from PharmExec website: https://www.pharmexec.com/view/crisis-communication-plans-in-pharma